S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end

Belite Bio (BLTE) Earnings Date, Estimates & Call Transcripts

$33.43
-1.17 (-3.38%)
(As of 04/19/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 8Estimated
Actual EPS
(Mar. 11)
-$0.25 Beat By $0.11
Consensus EPS
(Mar. 11)
-$0.36
Skip Charts & View Estimated and Actual Earnings Data

BLTE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BLTE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Belite Bio Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242($0.40)($0.27)($0.34)
Q2 20242($0.40)($0.27)($0.34)
Q3 20242($0.40)($0.27)($0.34)
Q4 20242($0.27)$1.29$0.51
FY 20248($1.47)$0.48($0.50)

BLTE Earnings Date and Information

Belite Bio last released its quarterly earnings results on March 11th, 2024. The reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.11. Belite Bio has generated ($1.24) earnings per share over the last year (($1.24) diluted earnings per share). Earnings for Belite Bio are expected to decrease in the coming year, from ($0.63) to ($0.80) per share. Belite Bio has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off prior year's report dates.

Belite Bio Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/8/2024
Estimated)
------- 
3/11/2024Q4 2023($0.36)($0.25)+$0.11($0.25)--
11/13/2023Q3 2023($0.31)($0.40)($0.09)($0.40)--
8/8/2023Q2 2023($0.23)($0.26)($0.03)($0.26)--  
5/10/2023Q1 2023($0.17)($0.33)($0.16)($0.33)--

Belite Bio Earnings - Frequently Asked Questions

When is Belite Bio's earnings date?

Belite Bio has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off last year's report dates. Learn more on BLTE's earnings history.

Did Belite Bio beat their earnings estimates last quarter?

In the previous quarter, Belite Bio (NASDAQ:BLTE) reported ($0.25) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.36) by $0.11. Learn more on analysts' earnings estimate vs. BLTE's actual earnings.

How much profit does Belite Bio generate each year?

Belite Bio (NASDAQ:BLTE) has a recorded net income of -$31.63 million. BLTE has generated -$1.24 earnings per share over the last four quarters.

What is Belite Bio's EPS forecast for next year?

Belite Bio's earnings are expected to decrease from ($0.63) per share to ($0.80) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:BLTE) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners